In response to the call for "Healthy China 2030" and the implementation of the national advocated transformation of the diagnosis and treatment model from "treatment centered" to "health centered", we practice the health concept of "early prevention, early screening, early diagnosis, and early treatment" that benefits the whole nation, and further enable top medical resources to benefit more patients. Through innovative diagnosis and treatment service models, Shenzhen New Frontier United Family Hospital has launched the "Famous Doctor's Opinion" online consultation service. The team led by Dean He Jianxing of the First Affiliated Hospital of Guangzhou Medical University will personally provide you with expert opinions.

 

High quality medical resources

Cloud sharing

 

Service Features

• Authoritative experts
Led by Professor He Jianxing, founder of minimally invasive thoracic surgery in China and director of the National Respiratory Medicine Center
 

• Precise diagnosis and treatment
Professional judgment based on over 40 years of clinical experience and more than 60000 surgical cases
 

• Convenient and efficient
Breaking through time and space limitations, achieving cloud based sharing of high-quality medical resources

 

Service flow

Visit the United Family Healthcare mini program
 

 

Select the city of Shenzhen, click on 'Famous Doctor's Opinion', and follow the steps to submit complete medical records and examination reports.

 

Notice

The opinions of renowned doctors are for consultation only and for reference only. Specific diagnosis and treatment opinions require an appointment with a doctor for a face-to-face consultation

After submitting the order, please make sure to add a dedicated customer service assistant and submit it DICOM Image format or cloud film connection

Urgent and critically ill patients are advised to seek medical attention promptly

 

National level celebrity

Assist in the diagnosis and treatment of lung diseases

Professor He Jianxing is the director of the National Respiratory Medicine Center, the dean of the Guangzhou Institute of Respiratory Health, and a leading figure in thoracic surgery, transplantation, and oncology at the First Affiliated Hospital of Guangzhou Medical University.
 

For over 40 years, from minimally invasive to minimally invasive, then to tubeless minimally invasive, multi arm multi hole robotic surgery, and finally to single arm single hole robotic surgery, innovation in vision AI Diagnosis, Professor He Jianxing's team has always been at the forefront of domestic and international thoracic surgery technology innovation, scientific research, and medical engineering integration. The main achievements include the world's first ductless airway surgery, needle endoscopy surgery, ectopic heart lung transplantation and other new transplantation technologies, Asia's first allogeneic tracheal transplantation, and China's first thoracoscopic lung cancer radical surgery; We have innovated and developed the minimally invasive technology system of thoracic surgery, improved the non-invasive early diagnosis technology of lung cancer, and formulated new personalized postoperative treatment strategies.

 

The "tubeless" minimally invasive thoracoscopy technology pioneered by it advocates the concept of minimally invasive and rapid recovery. Patients do not need endotracheal intubation during surgery, and during the surgery, they can maintain spontaneous breathing without the need for ventilators. There is no need to place chest tubes or urinary catheters after surgery. Patients who undergo this surgery can generally recover their eating and walking functions within 4 hours. Young patients can even walk directly from the recovery room to the ward after surgery, greatly reducing hospitalization time and improving the speed of recovery. Some can even be admitted within 24 hours. Unmanned minimally invasive thoracoscopic surgery has achieved the transformation of some chest surgeries into 'daytime surgeries'.

 

Clinical expertise mainly includes:

Precise diagnosis and treatment of lung cancer

Focused on early diagnosis and minimally invasive treatment of lung cancer, completed over 60000 lung cancer surgeries in total

Early diagnostic technology is internationally leading, with an accuracy rate of 100% for diagnosing small lung tumors

The 5-year survival rate of early lung cancer patients after surgery is as high as 80%, reaching the international leading level

The world's first "tubeless" minimally invasive technology (without endotracheal intubation/drainage tube/urinary catheter) enables day surgery in thoracic surgery
 

• Complex chest surgery

Breakthrough implementation of tracheal/esophageal replacement and reconstruction surgery

Innovative Application 3 D Image technology guidance for complex pulmonary artery repair

Establish standardized surgical procedures and complete lobectomy in as fast as 9 minutes

Pulmonary nodule resection can achieve 'same day surgery, same day discharge'
 

Surgical treatment for end-stage lung disease

Lung volume reduction surgery for advanced emphysema has a clinical effective rate of over 90%

Completed 73 lung transplant surgeries, setting a record for lung transplantation in an 81 year old patient
 

• Rapid rehabilitation minimally invasive technology

International first autonomous respiratory anesthesia thoracic surgery

The patient can get out of bed and move around within 4 hours after surgery

Shorten hospitalization time by more than 50% compared to traditional surgery

 

Professor He Jianxing

Founder, Professor/Chief Physician/Doctoral Supervisor of Minimally Invasive Thoracic Surgery in China
 

Current Position

• Director of the National Respiratory Medicine Center

• President of Guangzhou Institute of Respiratory Health

Leading figures in thoracic surgery, transplantation, and oncology at the First Affiliated Hospital of Guangzhou Medical University

Leading scientist at Guangzhou National Laboratory, American College of Surgeons, and Royal College of Surgeons in the UK Fellow

Member of the Academic Advisory Committee of the Chinese Academy of Medical Sciences

 

Major Achievements

• Major pioneers and guideline setters in minimally invasive thoracic surgery in China

Leading the way in China to carry out thoracoscopic surgery, the team has completed over 60000 minimally invasive thoracic surgeries

The first clinical allogeneic tracheal transplantation in Asia (1999)

The first clinical allogeneic single lung transplantation in South China (2003)

The record holder for the age of lung transplantation in China (successful surgery for an 81 year old patient)

• Published in top journals such as The Lancet SCI 79 papers with a total impact factor of 254+

 

Main Honors

First Prize of National Science and Technology Progress Award in 2020; 2018 National Science and Technology Progress Second Prize

2023 National Innovation Excellence Individual Award; 2021 National Innovation Excellence Group Award

2021 Guangdong Province Science and Technology Progress Special Award; First Prize of Guangdong Province Science and Technology Progress Award in 2023 and 2015

2024 Ho Leung Ho Lee Foundation Science and Technology Progress Award; The 10th Shulan Medical Award in 2023

2023 China Hospital Association R&D Innovation Award; 2021 National May Day Labor Medal Winners

• First Prize of Science and Technology Award of China Anti Cancer Association in 2024; First Prize of 2017 Chinese Medical Progress Award

2017 Huaxia Medical Technology First Prize; Second Prize for Scientific and Technological Progress in Chinese Universities in 2002

Second Prize for Scientific and Technological Progress in Guangdong Province in 1997; Expert with Outstanding Contributions in Guangdong Province in 1999

First Prize for Medical and Health Science and Technology Progress in Guangdong Province in 1997; First Prize of Guangzhou Science and Technology Progress Award in 1996

 

academic achievement

exist NEJM、Lancet、BMJ、Cell 430 papers (IF>30 points, 23 papers) have been published in well-known domestic and foreign journals; IF>10 Divided into 52 articles, total IF>3, 400 points, he cited>38000 times

ESI 22 highly cited papers; Top 10 Highly Cited Scholars in Chinese Respiratory and Extrathoracic Medicine

Tubeless Procedure has been included in Chapter 37 of the 2022 Harvard University Clinical Textbook